Standpoint Research Upgrades McKesson (MCK) to Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. IBM
4. PRIM
5. DPZ
6. ACN
7. NAVN
8. DFTX
9. META
10. KFY

Go back to Standpoint Research Upgrades McKesson (MCK) to Buy

Deutsche Bank Downgrades McKesson (MCK) to Hold

October 28, 2016 7:17 AM EDT

Deutsche Bank downgraded McKesson (NYSE: MCK) from Buy to Hold with a price target of $153.00 (from $196.00). Analyst George Hill expressed fears of a price war in drug wholesaling.

"MCK reported F2Q results below consensus, but it was the company's outlook and... More

Leerink Partners Downgrades McKesson (MCK) to Market Perform

October 28, 2016 7:08 AM EDT

Leerink Partners downgraded McKesson (NYSE: MCK) from Outperform to Market Perform with a price target of $160.00.

Analyst David Larsen commented, "MCK reported F2Q:17 adjusted EPS of $2.94 (-11% y/y) which was well below Leerink/Consensus of $3.10/$3.04. Management also reduced F2017 EPS... More

McKesson (MCK) Misses Q2 EPS by 11c; Updates FY17 EPS Outlook

October 27, 2016 4:14 PM EDT

McKesson (NYSE: MCK) reported Q2 EPS of $2.94, $0.11 worse than the analyst estimate of $3.05. Revenue for the quarter came in at $50 billion versus the consensus estimate of $51.21 billion.

GUIDANCE:

McKesson sees FY2017 EPS of $12.35-$12.85, versus the consensus of $13.59.

For earnings history and earnings-related data on McKesson (MCK) click here.

... More